Amaurosis fugax is a temporary loss of vision in one or both eyes due to a lack of blood flow to the retina. The retina is the light-sensitive layer of tissue at the back of the eyeball.
Causes
Amaurosis fugax is not itself a disease. Instead, it is a sign of other disorders. Amaurosis fugax can occur from different causes. One cause is when a blood clot or a piece of plaque blocks an artery in the eye. The blood clot or plaque usually travels from a larger artery, such as the carotid artery in the neck or an artery in the heart, to an artery in the eye.
Plaque is a hard substance that forms when fat, cholesterol, and other substances build up in the walls of arteries. Risk factors include:
- Heart disease, especially irregular heartbeat
- Overuse of alcohol
- Cocaine use
- Diabetes
- Family history of stroke
- High blood pressure
- High cholesterol
- Increasing age
- Smoking (people who smoke one pack a day double their risk for a stroke)
Amaurosis fugax can also occur because of other disorders such as:
- Other eye problems, such as inflammation of the optic nerve (optic neuritis)
- Blood vessel disease, such as temporal arteritis (giant cell arteritis) or polyarteritis nodosa
- Migraine headaches
- Brain tumor
- Head injury
- Multiple sclerosis (MS), inflammation of the nerves due to the body's immune cells attacking the nervous system
- Systemic lupus erythematosus, an autoimmune disease in which the body's immune cells attack healthy tissue throughout the body
Symptoms
Symptoms include the sudden loss of vision in one or both eyes. This usually lasts for a few seconds to several minutes. Afterward, vision returns to normal. Some people describe the loss of vision as a gray or black shade coming down over the eye.
Exams and Tests
Your health care provider will perform a complete eye and nervous system exam. In some cases, an eye exam will reveal a bright spot where the clot is blocking a retinal artery.
Tests that may be done include:
- Ultrasound or magnetic resonance angiography scan of the carotid artery to check for blood clots or plaque
- Blood tests to check cholesterol and blood sugar levels
- Tests of the heart, such as an electrocardiogram (ECG), or Holter monitor or loop recorder to check its electrical activity
- Echocardiogram to check the structure of the heart and to look for blood clots in the heart
Treatment
Treatment of amaurosis fugax depends on its cause. When amaurosis fugax is due to a blood clot or plaque, the concern is to prevent a stroke. The following can help prevent a stroke:
- Avoid fatty foods and follow a healthy, low-fat diet. Do not drink more than 1 to 2 alcoholic drinks a day.
- Exercise regularly; at least 30 minutes a day. Ask your provider what your goal should be.
- Quit smoking.
- Aim for a blood pressure below 120 to 130/80 mm Hg. If you have diabetes or have had a stroke, your provider may tell you to aim for a different blood pressure.
- Your LDL (bad) cholesterol should be lower than 70 mg/dL, if you have diabetes, heart disease or hardening of the arteries. Some experts recommend an even lower target, below 55 mg/dL.
- Follow your provider's treatment plans if you have high blood pressure, diabetes, high cholesterol, or heart disease.
- No treatment. You may only need regular visits to check the health of your heart and carotid arteries.
- Aspirin, or other blood-thinning medicines to lower your risk for stroke.
If a large part of the carotid artery appears blocked, carotid endarterectomy surgery is done to remove the blockage. The decision to do surgery is also based on your overall health.
Outlook (Prognosis)
Amaurosis fugax increases your risk for stroke.
When to Contact a Medical Professional
Contact your provider if any vision loss occurs. If symptoms last longer than a few minutes or if there are other symptoms with the vision loss, seek medical attention right away.
Alternative Names
Transient monocular blindness; Transient monocular visual loss; TMVL; Transient monocular visual loss; Transient binocular visual loss; TBVL; Temporary visual loss - amaurosis fugax
Images
References
Biller J, Schneck MJ, Ruland S. Ischemic cerebrovascular disease. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 65.
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153:e1154–e1276. PMID: 41824552 pubmed.ncbi.nlm.nih.gov/41824552/.
Brown GC, Sharma S, Brown MM. Ocular ischemic syndrome. In: Sadda SVR, Sarraf D, Freund KB, et al, eds. Ryan's Retina. 7th ed. Philadelphia, PA: Elsevier; 2023:chap 61.
Goldstein LB. Ischemic cerebrovascular disease. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 376.
Review Date 5/4/2026
Updated by: Joseph V. Campellone, MD, Professor of Neurology, Cooper-Inspira Neuroscience, Cooper Medical School of Rowan University, Camden, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.